About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
SGLT2i
- Company
- Ana Palanca
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 72 recruiting
Efficacy results: Not yet reported
72 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for SGLT2i and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT03878706
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
University of Athens 240 participants Est. completion 2027-06-30 1 siteType 2 diabetesView official trial listing → -
Recruiting NCT NCT04286399
Asian Diabetes Outcomes Prevention Trial
Not yet reported National Heart Centre Singapore 2400 participants Est. completion 2034-06-30 1 siteCardiovascular disease Other conditions: Diabetes MellitusView official trial listing → -
Recruiting NCT NCT04662723
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Not yet reported Fondazione Schena 878 participants Est. completion 2028-12-31 2 sites Stand-aloneOther conditions: Glomerulonephritis, Immunoglobulin A NephropathyView official trial listing → -
Recruiting NCT NCT05138575
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
Not yet reported University of Pennsylvania 53 participants Est. completion 2027-05-31 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT05180773
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Not yet reported Dennis M. McNamara, MD, MS 250 participants Est. completion 2028-12-31 64 sitesOther conditions: Peripartum Cardiomyopathy, PostpartumView official trial listing → -
Recruiting NCT NCT05349955
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
Not yet reported Shanghai Zhongshan Hospital 5600 participants Est. completion 2026-11-30 13 sites Stand-aloneType 2 diabetesChronic kidney disease Other conditions: Cardiovascular ComplicationView official trial listing → -
Recruiting NCT NCT05390892
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sitesCardiovascular disease Other conditions: Type2DiabetesView official trial listing → -
Recruiting NCT NCT05521984
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Not yet reported Washington University School of Medicine 20 participants Est. completion 2031-06-30 1 siteOther conditions: Pediatric Brain Tumor, Pediatric Solid TumorView official trial listing → -
Recruiting NCT NCT05612594
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
Not yet reported Yale University 164 participants Est. completion 2027-09 2 sitesOther conditions: Sleep ApneaView official trial listing → -
Recruiting NCT NCT05660083
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Not yet reported The Methodist Hospital Research Institute 36 participants Est. completion 2028-12-02 3 sites Stand-aloneOther conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast CancerView official trial listing → -
Recruiting NCT NCT05663515
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca 24000 participants Est. completion 2026-10-01 8 sitesOther conditions: Pancreatic CancerView official trial listing → -
Recruiting NCT NCT05786443
Safety and Efficacy of Empagliflozin in Hemodialysis
Not yet reported NYU Langone Health 60 participants Est. completion 2026-12-30 2 sites Stand-aloneOther conditions: End Stage Renal DiseaseView official trial listing → -
Recruiting NCT NCT06024746
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Not yet reported Colorado Prevention Center 1500 participants Est. completion 2027-11 140 sitesHeart failureView official trial listing → -
Recruiting NCT NCT06030843
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Not yet reported, Not yet reported Chulalongkorn University 200 participants Est. completion 2026-12-31 1 siteOther conditions: Empagliflozin in Cardiorenal Syndrome Type 1View official trial listing → -
Recruiting NCT NCT06082063
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Not yet reported Steno Diabetes Center Copenhagen 2000 participants Est. completion 2029-07-01 2 sitesCardiovascular diseaseHeart failure Other conditions: Type 1 Diabetes, Kidney FailureView official trial listing → -
Recruiting NCT NCT06091475
Therapy to Maintain Remission in Dilated Cardiomyopathy
Not yet reported Imperial College London 50 participants Est. completion 2026-09-15 1 siteHeart failure Other conditions: Cardiomyopathy, Dilated, Cardiomyopathies, Heart DiseasesView official trial listing → -
Recruiting NCT NCT06128980
Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy
Not yet reported, Not yet reported Herlev and Gentofte Hospital 348 participants Est. completion 2032-01 1 siteHeart failure Other conditions: Heart Rhythm DisorderView official trial listing → -
Recruiting NCT NCT06142474
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
Not yet reported National Taiwan University Hospital 450 participants Est. completion 2030-10-09 1 site Stand-aloneHeart failure Other conditions: Ventilator LungView official trial listing → -
Recruiting NCT NCT06143566
Polypill for Prevention of Cardiomyopathy
Not yet reported, Not yet reported University of Texas Southwestern Medical Center 200 participants Est. completion 2027-12-01 1 siteType 2 diabetes Other conditions: High Blood PressureView official trial listing → -
Recruiting NCT NCT06183437
The STOP-MED CTRCD Trial
Not yet reported Dinesh Thavendiranathan 335 participants Est. completion 2031-12 14 sites Stand-aloneHeart failure Other conditions: Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, CancerView official trial listing → -
Recruiting NCT NCT06260059
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Not yet reported Anita Saraf 40 participants Est. completion 2027-06-01 3 sitesHeart failure Other conditions: Adult Congenital Heart DiseaseView official trial listing → -
Recruiting NCT NCT06283420
Metabolic Response to the Initiation of Heart Failure Therapy
Vojtech Melenovsky, MD, PhD 120 participants Est. completion 2026-12-20 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT06285760
Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)
Puerta de Hierro University Hospital 64 participants Est. completion 2026-12-31 1 siteHeart failure Other conditions: Persistent CongestionView official trial listing → -
Recruiting NCT NCT06291155
Mechanism of SGLT2 Inhibition in the Kidney
Not yet reported University of Michigan 20 participants Est. completion 2028-02-28 1 siteType 2 diabetesChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT06364930
SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
Not yet reported Chinese University of Hong Kong 412 participants Est. completion 2031-03-30 1 siteOther conditions: Chronic Hepatitis BView official trial listing → -
Recruiting NCT NCT06410352
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Not yet reported University Medical Center, Kazakhstan 220 participants Est. completion 2026-07-31 1 siteMetabolic syndromeView official trial listing → -
Recruiting NCT NCT06430684
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Not yet reported Ann & Robert H Lurie Children's Hospital of Chicago 40 participants Est. completion 2026-11-01 1 site Stand-aloneChronic kidney disease Other conditions: Pediatric Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06520891
"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
Fayoum University 90 participants Est. completion 2025-12-30 1 siteOther conditions: 2 Drugs Are Statin and SGLT2iView official trial listing → -
Recruiting NCT NCT06528405
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Not yet reported National Taiwan University Hospital 264 participants Est. completion 2027-12 1 site Stand-aloneOther conditions: Acute Kidney InjuryView official trial listing → -
Recruiting NCT NCT06585761
Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients
Kafrelsheikh University 60 participants Est. completion 2025-06-30 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT06609356
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Not yet reported Vanderbilt University Medical Center 27 participants Est. completion 2027-12 1 site Stand-aloneOther conditions: Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy VolunteerView official trial listing → -
Recruiting NCT NCT06625073
Randomized Trial of SGLT2i in Heart Transplant Recipients
Not yet reported VA Office of Research and Development 200 participants Est. completion 2030-02-28 6 sitesCardiovascular disease Other conditions: Heart Transplant, Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06627322
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Not yet reported Kyu Chang Won 5950 participants Est. completion 2029-09-30 2 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT06655480
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Not yet reported National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 50 participants Est. completion 2027-12-31 1 siteHeart failure Other conditions: LVDD, Myocardial FibrosisView official trial listing → -
Recruiting NCT NCT06674109
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
Not yet reported Massachusetts General Hospital 60 participants Est. completion 2028-02-28 1 siteOther conditions: Gout and HyperuricemiaView official trial listing → -
Recruiting NCT NCT06676384
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Not yet reported Christian Medical College, Vellore, India 585 participants Est. completion 2029-08 12 sitesOther conditions: IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA GlomerulonephritisView official trial listing → -
Recruiting NCT NCT06727409
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
Not yet reported Chinese University of Hong Kong 82 participants Est. completion 2026-12-31 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT06753994
Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors
Not yet reported McGill University 24 participants Est. completion 2027-01-01 1 site Stand-aloneOther conditions: Diabetes, Type1diabetes, T1DView official trial listing → -
Recruiting NCT NCT06838286
Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
Chong Kun Dang Pharmaceutical 10000 participants Est. completion 2029-12-31 1 siteType 2 diabetesView official trial listing → -
Recruiting NCT NCT06863532
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 80 participants Est. completion 2026-09-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT06929169
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Not yet reported Maximo Agustin Schiavone 80 participants Est. completion 2026-08 1 site Stand-aloneChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT06932081
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Leiden University Medical Center 400 participants Est. completion 2027-12-31 11 sitesOther conditions: Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)View official trial listing → -
Recruiting NCT NCT06983054
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Not yet reported Amsterdam UMC, location VUmc 34 participants Est. completion 2025-12 2 sitesType 2 diabetesView official trial listing → -
Recruiting NCT NCT07019012
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
Not yet reported Huazhong University of Science and Technology 170 participants Est. completion 2026-12-30 2 sites Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07053293
SGLT2i, Hepatic Glucose Production, and SNS
Not yet reported The University of Texas Health Science Center at San Antonio 22 participants Est. completion 2027-06-30 1 site Added to GLP-1Type 2 diabetesView official trial listing → -
Recruiting NCT NCT07053306
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
Not yet reported The University of Texas Health Science Center at San Antonio 29 participants Est. completion 2027-06-30 1 site Added to GLP-1Type 2 diabetesView official trial listing → -
Recruiting NCT NCT07053319
SGLT2i, Pioglitazone, and Ketone Production in T2D
Not yet reported The University of Texas Health Science Center at San Antonio 64 participants Est. completion 2027-06-30 1 site Added to GLP-1Type 2 diabetesView official trial listing → -
Recruiting NCT NCT07055282
SGLT2i in Kidney Stones
Not yet reported University of Chicago 32 participants Est. completion 2028-11-01 1 siteOther conditions: Kidney StonesView official trial listing → -
Recruiting NCT NCT07056699
SGLT2i, Pioglitazone, and Ketone Production in T1D
Not yet reported The University of Texas Health Science Center at San Antonio 24 participants Est. completion 2027-06-30 1 siteOther conditions: Type1diabetesView official trial listing → -
Recruiting NCT NCT07110415
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Not yet reported SPH Qingdao Growful Pharmacetical Co.,Ltd 2708 participants Est. completion 2030-12-31 96 sites Stand-aloneOther conditions: Coronary Heart Disease, Cardiac DysfunctionView official trial listing → -
Recruiting NCT NCT07119424
Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications
Chiara Lanzani 300 participants Est. completion 2027-02 1 siteOther conditions: Elderly Patients (>65 Years), Diabetes (DM), Heart Disease, Renal Diseases, Internal DiseaseView official trial listing → -
Recruiting NCT NCT07143773
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients
Not yet reported Odense University Hospital 88 participants Est. completion 2027-08-01 1 siteOther conditions: Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial, Placebo Control DesignView official trial listing → -
Recruiting NCT NCT07157475
Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
Wroclaw Medical University 300 participants Est. completion 2026-12-31 1 siteOther conditions: Peripheral Arterial Disease(PAD)View official trial listing → -
Recruiting NCT NCT07169422
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
Not yet reported Nova Scotia Health Authority 120 participants Est. completion 2028-07-01 1 siteChronic kidney diseaseType 2 diabetesView official trial listing → -
Recruiting NCT NCT07172971
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Not yet reported Vanderbilt University Medical Center 10 participants Est. completion 2028-02-01 1 siteOther conditions: Duchenne Muscular Dystrophy (DMD)View official trial listing → -
Recruiting NCT NCT07228195
SGLT2i Therapy in Islet Transplantation (SIT)
Not yet reported University of Minnesota 40 participants Est. completion 2028-12-01 1 siteOther conditions: Partial Islet Function, TPIAT, DiabetesView official trial listing → -
Recruiting NCT NCT07244003
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 430 participants Est. completion 2028-06-30 1 siteType 2 diabetesView official trial listing → -
Recruiting NCT NCT07273838
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
Not yet reported Yale University 130 participants Est. completion 2029-10-31 2 sites Stand-aloneHeart failure Other conditions: Acute Kidney InjuryView official trial listing → -
Recruiting NCT NCT07280585
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Not yet reported University of Cologne 420 participants Est. completion 2030-05-15 30 sitesOther conditions: Polycystic Kidney, Autosomal DominantView official trial listing → -
Recruiting NCT NCT07292909
Effect of Empagliflozin on Inflammation
Not yet reported Hotel Dieu de France Hospital 100 participants Est. completion 2027-09-30 1 siteCardiovascular disease Other conditions: Inflamation, PCI, SGLT 2 InhibitorsView official trial listing → -
Recruiting NCT NCT07309094
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 siteChronic kidney diseaseType 2 diabetes Other conditions: ObesityView official trial listing → -
Recruiting NCT NCT07434791
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Not yet reported Sunnybrook Health Sciences Centre 100 participants Est. completion 2029-09 1 site Stand-aloneChronic kidney diseaseType 2 diabetesView official trial listing → -
Recruiting NCT NCT07444203
Transformative Research in Diabetic Nephropathy 2.0
University of Pennsylvania 200 participants Est. completion 2028-11-12 1 siteType 2 diabetes Other conditions: Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, ChronicView official trial listing → -
Recruiting NCT NCT07469943
The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction
University of Athens 80 participants Est. completion 2028-12-20 1 siteCardiovascular disease Other conditions: Diabete Type 2View official trial listing → -
Recruiting NCT NCT07482020
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
Not yet reported Huashan Hospital 66 participants Est. completion 2027-06-30 1 siteOther conditions: Atrial Fibrillation (AF), HypertensionView official trial listing → -
Recruiting NCT NCT07491042
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Not yet reported Oman Ministry of Health 38 participants Est. completion 2027-01-31 1 site Stand-aloneOther conditions: End Stage Chronic Renal FailureView official trial listing → -
Recruiting NCT NCT07513883
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Not yet reported Ziekenhuis Oost-Limburg 100 participants Est. completion 2028-12 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT07569640
HFrEF Polypill in Sri Lanka RCT
Not yet reported Washington University School of Medicine 1672 participants Est. completion 2029-04 11 sites Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT07572032
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
Not yet reported Kyungsub Song 80 participants Est. completion 2028-12-20 4 sites Stand-aloneCardiovascular diseaseHeart failure Other conditions: Valvular CardiomyopathyView official trial listing → -
Recruiting NCT NCT07631156
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
Not yet reported Kyungsub Song 80 participants Est. completion 2029-12-30 5 sites Stand-aloneHeart failure Other conditions: Ventricular Dysfunction, LeftView official trial listing → -
Recruiting NCT NCT07684326
"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
Not yet reported, Not yet reported Beni-Suef University 52 participants Est. completion 2027-09 1 siteOther conditions: Ascites HepaticView official trial listing → -
Recruiting NCT NCT07700940
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Not yet reported Ahmed Yehia Ismail 66 participants Est. completion 2026-12-30 1 site Stand-aloneOther conditions: Lupus Nephritis (LN)View official trial listing → -
Completed NCT NCT02653209
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
Not yet reported Royal Devon and Exeter NHS Foundation Trust 525 participants Est. completion 2021-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02773368
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Not yet reported Novo Nordisk A/S 420 participants Est. completion 2017-10-23 88 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT02846233
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
Not yet reported University of California, San Francisco 22 participants Est. completion 2018-12 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02857764
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
Janssen Research & Development, LLC 127690 participants Est. completion 2017-06-30Type 2 diabetesView official trial listing → -
Completed NCT NCT02964247
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Not yet reported Novo Nordisk A/S 303 participants Est. completion 2018-05-08 82 sites Added to GLP-1Type 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT02993614
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
AstraZeneca 99999 participants Est. completion 2020-12-17 17 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03050229
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
Not yet reported Jichi Medical University 174 participants Est. completion 2018-03 12 sitesType 2 diabetes Other conditions: Nocturnal HypertensionView official trial listing → -
Completed NCT NCT03086330
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Not yet reported Novo Nordisk A/S 302 participants Est. completion 2018-08-06 72 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT03122834
Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure
Ain Shams University 246 participants Est. completion 2024-06-14 1 siteHeart failureView official trial listing → -
Completed NCT NCT03188887
Treatment of IgA Nephropathy According to Renal Lesions
Not yet reported Assistance Publique - Hôpitaux de Paris 62 participants Est. completion 2024-01-12 1 site Stand-aloneOther conditions: IgA NephropathyView official trial listing → -
Completed NCT NCT03249506
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Janssen Research & Development, LLC 25358 participants Est. completion 2017-11-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03282136
SGLT2i and Incretin and CRTd.
Not yet reported University of Campania Luigi Vanvitelli 500 participants Est. completion 2024-09-01 1 siteType 2 diabetesHeart failureView official trial listing → -
Completed NCT NCT03366181
SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.
University of Campania Luigi Vanvitelli 500 participants Est. completion 2017-11-26 1 siteHeart failureType 2 diabetes Other conditions: ICD, SGLT2iView official trial listing → -
Status unknown NCT NCT03398577
Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease
Not yet reported Sheba Medical Center 61 participants Est. completion 2018-12-31 1 siteOther conditions: Coronary Disease With Diabetes MellitusView official trial listing → -
Status unknown NCT NCT03631134
Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin
Not yet reported Nanjing First Hospital, Nanjing Medical University 100 participants Est. completion 2019-01-30 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03646292
Antidiabetic Drugs for Steatotic Liver Disease
Not yet reported Yonsei University 51 participants Est. completion 2022-06-16 1 siteMASLDType 2 diabetes Other conditions: Digestive System Disease, Liver Diseases, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, ThiazolidinedionesView official trial listing → -
Withdrawn NCT NCT03813316
Approaches To Therapy Escalation In T2D
Not yet reported LMC Diabetes & Endocrinology Ltd. Est. completion 2019-09-18 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03817463
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Boehringer Ingelheim 327624 participants Est. completion 2021-12-10 13 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03871621
Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial
Not yet reported Mackay Memorial Hospital 76 participants Est. completion 2022-08-31 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT03917758
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Not yet reported University of Turin, Italy 30 participants Est. completion 2020-10-30 1 site Stand-aloneType 2 diabetes Other conditions: Arterial Hypertension, Body Weight ChangesView official trial listing → -
Completed NCT NCT03918148
Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03951805
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
Not yet reported Novo Nordisk A/S 205 participants Est. completion 2020-01-17 43 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03979352
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
Not yet reported Samuel Lunenfeld Research Institute, Mount Sinai Hospital 28 participants Est. completion 2021-08-31 2 sitesOther conditions: Type1 Diabetes MellitusView official trial listing → -
Status unknown NCT NCT04146155
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 200 participants Est. completion 2021-12-31 1 site Added to GLP-1Type 2 diabetes Other conditions: Peripheral Vascular Disorder Due to Diabetes MellitusView official trial listing → -
Completed NCT NCT04149067
Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 1080 participants Est. completion 2019-03-15 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04184947
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
University of Padova 10000 participants Est. completion 2020-02-29 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04196231
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT04242758
Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy
Not yet reported University of Pisa 30 participants Est. completion 2020-04-01 1 site Stand-aloneOther conditions: Renal Function Disorder, Glucose Metabolism DisordersView official trial listing → -
Completed NCT NCT04304261
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Not yet reported Third Military Medical University 100 participants Est. completion 2024-04-30 1 siteType 2 diabetes Other conditions: Cognitive Functions ConfusionView official trial listing → -
Active, not recruiting NCT NCT04333823
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
Not yet reported The Hospital for Sick Children 100 participants Est. completion 2024-05 3 sitesOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT04342819
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
Not yet reported, Not yet reported The University of The West Indies 25 participants Est. completion 2021-12-31 1 site Stand-aloneOther conditions: Platelet Dysfunction Due to DrugsView official trial listing → -
Completed NCT NCT04350593
Dapagliflozin in Respiratory Failure in Patients With COVID-19
Not yet reported Saint Luke's Health System 1250 participants Est. completion 2021-06-11 95 sitesOther conditions: COVID-19View official trial listing → -
Completed NCT NCT04400760
The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
Not yet reported, Not yet reported The University of The West Indies 40 participants Est. completion 2022-06-30 1 siteOther conditions: Platelet DysfunctionView official trial listing → -
Completed NCT NCT04523064
POST-CABGDM: Empagliflozin in Perioperative CABG
Not yet reported University of Sao Paulo General Hospital 155 participants Est. completion 2024-01-30 1 siteType 2 diabetesCardiovascular disease Other conditions: Coronary Artery Bypass Surgery, Acute Kidney InjuryView official trial listing → -
Completed NCT NCT04534270
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Not yet reported Children's Hospital of Fudan University 23 participants Est. completion 2022-03-30 1 siteOther conditions: ProteinuriaView official trial listing → -
Completed NCT NCT04545411
Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
Not yet reported, Not yet reported University of California, San Diego 12 participants Est. completion 2022-10-31 1 siteOther conditions: Type 1 DiabetesView official trial listing → -
Status unknown NCT NCT04626323
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
Not yet reported Hospital Alemão Oswaldo Cruz 60 participants Est. completion 2024-12 1 site Stand-aloneType 2 diabetes Other conditions: Kidney Disease, Chronic, Kidney InjuryView official trial listing → -
Withdrawn NCT NCT04697485
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
Not yet reported Northwestern University Est. completion 2022-03-30 1 site Stand-aloneHeart failure Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT04700839
SGLT2 Inhibitors in Patients With PCOS
Not yet reported Shanghai 10th People's Hospital 68 participants Est. completion 2021-04-30 1 site Stand-aloneOther conditions: Polycystic Ovary SyndromeView official trial listing → -
Completed NCT NCT04735042
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
University of Pisa 60 participants Est. completion 2022-04-07 1 siteType 2 diabetes Other conditions: Urinary Tract InfectionsView official trial listing → -
Completed NCT NCT04791826
Electronic Alerts for Heart Failure Prevention in Diabetes
Not yet reported University of Texas Southwestern Medical Center 1524 participants Est. completion 2024-05-07 1 site Stand-aloneHeart failureType 2 diabetesView official trial listing → -
Status unknown NCT NCT04853615
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
Fayoum University 800 participants Est. completion 2024-08-01Other conditions: SGLT2i Kideny Protection Against Contrast in Diabetic KidneyView official trial listing → -
Status unknown NCT NCT04860011
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance
Not yet reported NHS Greater Glasgow and Clyde 61 participants Est. completion 2023-04-03 2 sites Stand-aloneHeart failureView official trial listing → -
Status unknown NCT NCT04862858
Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes
Not yet reported Humana Inc. 4197 participants Est. completion 2022-08-16 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Completed NCT NCT05021419
Efficacy of a Streamlined Heart Failure Optimization Protocol
Not yet reported The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust 60 participants Est. completion 2024-01-07 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT05033054
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
University of Texas Southwestern Medical Center 33 participants Est. completion 2025-02-01 1 siteOther conditions: Kidney Disease, Chronic, DiabetesView official trial listing → -
Completed NCT NCT05073692
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Kaiser Permanente 241981 participants Est. completion 2025-03-12 6 sitesType 2 diabetesCardiovascular diseaseView official trial listing → -
Active, not recruiting NCT NCT05090358
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Not yet reported Memorial Sloan Kettering Cancer Center 15 participants Est. completion 2027-10-08 9 sites Stand-aloneOther conditions: Breast Cancer, Breast Cancer Stage IV, Metastatic Breast CancerView official trial listing → -
Terminated NCT NCT05129722
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Not yet reported The George Institute 3 participants Est. completion 2024-05-01 2 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT05214573
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
Mayo Clinic 386301 participants Est. completion 2025-07-22 1 siteType 2 diabetes Other conditions: Cardiac DiseaseView official trial listing → -
Active, not recruiting NCT NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 siteType 2 diabetes Other conditions: Cardiovascular Events, Renal DiseaseView official trial listing → -
Completed NCT NCT05233163
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Not yet reported Columbia University 15 participants Est. completion 2023-05-01 1 siteOther conditions: Transthyretin Amyloid CardiomyopathyView official trial listing → -
Status unknown NCT NCT05252624
Henagliflozin in Patients With Atrial Fibrillation
Not yet reported Beijing Anzhen Hospital 100 participants Est. completion 2023-09-30 1 siteOther conditions: Atrial FibrillationView official trial listing → -
Completed NCT NCT05278962
HF Patients With LVADs Being Treated With SGLT2i
Not yet reported University of Chicago 32 participants Est. completion 2025-08-31 1 siteHeart failureView official trial listing → -
Active, not recruiting NCT NCT05295368
Strategies for Kidney Outcomes Prevention and Evaluation - The SKOPE Study
Not yet reported Duke-NUS Graduate Medical School 724 participants Est. completion 2027-12 1 siteChronic kidney diseaseView official trial listing → -
Status unknown NCT NCT05310916
Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients
Not yet reported Nidae Alaa 60 participants Est. completion 2023-11 1 siteOther conditions: Diabetic RetinopathyView official trial listing → -
Completed NCT NCT05344963
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
Matteo Cameli 503 participants Est. completion 2024-06-01 1 siteHeart failure Other conditions: Sodium-GLucose coTransporter-2 InhibitorsView official trial listing → -
Terminated NCT NCT05346653
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Not yet reported University of Chicago 1 participants Est. completion 2023-05-23 1 siteHeart failureView official trial listing → -
Completed NCT NCT05350202
Emp-Activity: Empagliflozin Functional Capacity
Boehringer Ingelheim 3431 participants Est. completion 2024-07-25 350 sitesHeart failureView official trial listing → -
Completed NCT NCT05390307
Obesity Treatment to Improve Diabetes
Not yet reported Dasman Diabetes Institute 60 participants Est. completion 2024-01-01 1 site MixedOther conditions: Type 1 DiabetesView official trial listing → -
Completed NCT NCT05402579
Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk
Mount Sinai Hospital, Canada 63 participants Est. completion 2025-01-20 2 sitesOther conditions: Diabetes Type 2, DKA, Diabetic KetoacidosisView official trial listing → -
Completed NCT NCT05413369
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Not yet reported Sanofi 582 participants Est. completion 2023-10-20 60 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT05465317
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
Boehringer Ingelheim 62197 participants Est. completion 2023-05-02 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05526157
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
Bayer 50000 participants Est. completion 2024-09-05 5 sitesChronic kidney diseaseType 2 diabetesView official trial listing → -
Completed NCT NCT05535322
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
Ana Palanca 26944 participants Est. completion 2022-09-01 1 siteType 2 diabetes Other conditions: ObesityView official trial listing → -
Completed NCT NCT05541484
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
Not yet reported Washington University School of Medicine 21 participants Est. completion 2023-12-23 1 siteOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Active, not recruiting NCT NCT05572957
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2027-10 6 sitesHeart failure Other conditions: Non-ischemic Cardiomyopathy, Left Bundle-Branch BlockView official trial listing → -
Active, not recruiting NCT NCT05590143
proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2
Not yet reported Amsterdam UMC 784 participants Est. completion 2025-09 6 sitesOther conditions: Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 InhibitorView official trial listing → -
Status unknown NCT NCT05605158
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
Not yet reported Tanta University 56 participants Est. completion 2024-11 1 siteOther conditions: Non Alcoholic SteatohepatitisView official trial listing → -
Status unknown NCT NCT05623358
PHARM Optimal-HF Pilot
Not yet reported University of British Columbia 42 participants Est. completion 2025-09-01 1 site Stand-aloneHeart failureView official trial listing → -
Active, not recruiting NCT NCT05637853
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
Not yet reported Göteborg University 60 participants Est. completion 2026-08-26 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT05640180
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
Bayer 17847 participants Est. completion 2023-12-20 1 siteChronic kidney diseaseType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT05662865
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
Not yet reported AdventHealth Translational Research Institute 9 participants Est. completion 2026-12 1 site Stand-aloneOther conditions: Ketones, MetabolismView official trial listing → -
Completed NCT NCT05677334
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Not yet reported First Affiliated Hospital of Guangxi Medical University 210 participants Est. completion 2024-10-30 1 siteOther conditions: Type2diabetesView official trial listing → -
Completed NCT NCT05704088
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
Not yet reported Mansoura University 100 participants Est. completion 2024-01-08 1 siteOther conditions: SGLT2 INHIBITORS, Lupus Nephritis, BMDView official trial listing → -
Completed NCT NCT05727579
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Not yet reported Amsterdam UMC, location VUmc 41 participants Est. completion 2025-11-30 1 siteChronic kidney disease Other conditions: Diabetes Mellitus, HypertensionView official trial listing → -
Completed NCT NCT05734690
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
Not yet reported Brigham and Women's Hospital 503 participants Est. completion 2025-06-09 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT05735197
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
Not yet reported Mansoura University 100 participants Est. completion 2023-11-01 1 siteChronic kidney disease Other conditions: Bone Diseases, MetabolicView official trial listing → -
Completed NCT NCT05748925
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
Not yet reported Mansoura University 84 participants Est. completion 2024-01-01 1 siteOther conditions: SLE, Lupus Nephritis, SGLT2 InhibitorsView official trial listing → -
Completed NCT NCT05757193
Ketone Pharmacokinetic Study in HFrEF
Not yet reported Duke University 20 participants Est. completion 2024-01-11 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT05799638
Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT
Chongqing Medical University 263 participants Est. completion 2024-06-30 1 siteHeart failureView official trial listing → -
Completed NCT NCT05834738
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Not yet reported Novartis Pharmaceuticals 54 participants Est. completion 2025-10-29 30 sitesOther conditions: IgA Nephropathy, Immunoglobulin A NephropathyView official trial listing → -
Active, not recruiting NCT NCT05882071
Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France
Boehringer Ingelheim 547150 participants Est. completion 2026-08-31 1 siteType 2 diabetesView official trial listing → -
Terminated NCT NCT05897372
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
Not yet reported Iain Bressendorff 1 participants Est. completion 2024-09-23 1 site Stand-aloneChronic kidney diseaseView official trial listing → -
Status unknown NCT NCT05922852
Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein
Peking University Third Hospital 1000 participants Est. completion 2024-02-28 2 sitesType 2 diabetes Other conditions: Antidiabetic DrugsView official trial listing → -
Status unknown NCT NCT05948969
Transform CV Risk in Diabetes
Not yet reported American College of Cardiology 750 participants Est. completion 2024-12-31 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05953701
Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
AstraZeneca 800211 participants Est. completion 2023-09-30 1 siteChronic kidney diseaseView official trial listing → -
Completed NCT NCT05966792
SGLT2 Inhibitors in Treating Patients With PCOS
Not yet reported Shanghai 10th People's Hospital 82 participants Est. completion 2025-06-30 1 site Stand-aloneOther conditions: Polycystic Ovary SyndromeView official trial listing → -
Completed NCT NCT05986695
Informational Nudge to Improve Heart Failure Prescribing
Not yet reported VA Office of Research and Development 81 participants Est. completion 2024-10-31 1 siteHeart failureView official trial listing → -
Completed NCT NCT05989503
Initiation of ARNi and SGLT2i in Patients With HFrEF
Not yet reported Universidade do Porto 62 participants Est. completion 2025-07-31 5 sitesHeart failureView official trial listing → -
Completed NCT NCT05990296
Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care
Not yet reported Geisinger Clinic 4306 participants Est. completion 2025-05-17 1 siteHeart failureView official trial listing → -
Completed NCT NCT05998837
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
Not yet reported, Not yet reported IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 34 participants Est. completion 2024-09-30 1 siteChronic kidney diseaseType 2 diabetes Other conditions: HypertensionView official trial listing → -
Active, not recruiting NCT NCT05999773
SGLT-2 Inhibitors in the Treatment of Ascites
University of Palermo 40 participants Est. completion 2026-12-31 2 sitesOther conditions: Ascites Hepatic, Cirrhosis, Liver, Diabete Type 2View official trial listing → -
Active, not recruiting NCT NCT06000462
The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes
Not yet reported Oman Ministry of Health 150 participants Est. completion 2025-12-30 1 siteOther conditions: Obesity, Dapagliflozin Adverse Reaction, Weight Loss, Effect of DrugView official trial listing → -
Status unknown NCT NCT06007157
Sodium Glucose Cotransporter-2 Inhibitors and Salt-sensitivity in Type 2 Diabetes
Not yet reported Azienda Ospedaliero, Universitaria Pisana 30 participants Est. completion 2025-03-01 1 site Stand-aloneOther conditions: Blood Pressure, Salt; Excess, Diabete Type 2View official trial listing → -
Status unknown NCT NCT06021145
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 46 participants Est. completion 2025-05 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing → -
Completed NCT NCT06029712
Heart Failure Polypill at a Safety Net Hospital
Not yet reported University of California, San Francisco 35 participants Est. completion 2025-01-29 1 site Stand-aloneHeart failure Other conditions: HIV InfectionsView official trial listing → -
Completed NCT NCT06065280
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Not yet reported Damanhour University 80 participants Est. completion 2024-12-30 1 siteHeart failureView official trial listing → -
Status unknown NCT NCT06080802
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Not yet reported, Not yet reported October University for Modern Sciences and Arts 80 participants Est. completion 2024-12-01 1 site Stand-aloneHeart failure Other conditions: Diabete Type 2View official trial listing → -
Status unknown NCT NCT06097585
Gliflozins on HF in Regurgitant Rheumatic Heart
Assiut University 150 participants Est. completion 2025-04-01Heart failure Other conditions: Rheumatic Heart DiseaseView official trial listing → -
Completed NCT NCT06111768
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
Not yet reported Yale University 30 participants Est. completion 2025-12-25 1 site Stand-aloneOther conditions: Cardiorenal SyndromeView official trial listing → -
Status unknown NCT NCT06113900
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
Not yet reported, Not yet reported Ain Shams University 50 participants Est. completion 2025-01-30 1 siteOther conditions: Lupus NephritisView official trial listing → -
Terminated NCT NCT06124924
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Not yet reported University of Minnesota 1 participants Est. completion 2024-08-16 1 site Stand-aloneOther conditions: Acute Kidney InjuryView official trial listing → -
Status unknown NCT NCT06142006
The Diabetes Staging System in Patient Aligned Care Teams
Durham VA Medical Center 120 participants Est. completion 2025-09-01 1 siteType 2 diabetes Other conditions: Diabetes MellitusView official trial listing → -
Status unknown NCT NCT06147271
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Not yet reported Universidade Federal do Ceara 80 participants Est. completion 2025-08-01 1 siteOther conditions: Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart TransplantView official trial listing → -
Completed NCT NCT06150924
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Not yet reported Mineralys Therapeutics Inc. 60 participants Est. completion 2025-04-23 44 sites Stand-aloneChronic kidney diseaseView official trial listing → -
Completed NCT NCT06171802
EMPagliflozin After Aortic Valve Replacement
Not yet reported Rigshospitalet, Denmark 206 participants Est. completion 2026-05-18 1 siteOther conditions: Aortic Valve StenosisView official trial listing → -
Status unknown NCT NCT06187493
Treatment of Patients With Diabetic Kidney Disease
Not yet reported Assiut University 70 participants Est. completion 2025-12-31Chronic kidney diseaseView official trial listing → -
Status unknown NCT NCT06201000
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
October 6 University 282 participants Est. completion 2024-09-01 1 siteHeart failure Other conditions: Genetic PolymorphismsView official trial listing → -
Status unknown NCT NCT06245980
Role of SGLT2I in Patients With Myocardial Infarction
Dongying Zhang 1200 participants Est. completion 2024-03-31 1 siteCardiovascular disease Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT06268977
Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes
Not yet reported Assiut University 482 participants Est. completion 2026-01-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT06344247
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
Not yet reported RenJi Hospital 48 participants Est. completion 2025-12-01 1 site MixedChronic kidney disease Other conditions: ObesityView official trial listing → -
Completed NCT NCT06393348
Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
Not yet reported Shandong Suncadia Medicine Co., Ltd. 155 participants Est. completion 2025-03-13 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT06401343
Use of SGLT2i in noHCM With HFpEF
Not yet reported China National Center for Cardiovascular Diseases 94 participants Est. completion 2025-08-01 1 siteHeart failure Other conditions: Hypertrophic CardiomyopathyView official trial listing → -
Status unknown NCT NCT06417320
Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years
Not yet reported Mansoura University 60 participants Est. completion 2025-08 1 siteOther conditions: Nephrotic Syndrome in ChildrenView official trial listing → -
Terminated NCT NCT06450522
Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF)
Not yet reported University of British Columbia 12 participants Est. completion 2025-02-21 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT06453577
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
Universität des Saarlandes 33 participants Est. completion 2026-07-08 1 siteHeart failureView official trial listing → -
Completed NCT NCT06469645
The Role of SGLT2i in Management of Moderate AS
Not yet reported, Not yet reported University of East Anglia 104 participants Est. completion 2026-07-24 1 siteOther conditions: Moderate Aortic Valve StenosisView official trial listing → -
Status unknown NCT NCT06535529
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Not yet reported Helwan University 60 participants Est. completion 2025-09-01 1 siteHeart failureView official trial listing → -
Not yet recruiting NCT NCT06604611
Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation
Not yet reported Dongying Zhang 200 participants Est. completion 2026-03-31 1 site Stand-aloneHeart failure Other conditions: Chronic Inflammation, Inflammation, ColchicineView official trial listing → -
Completed NCT NCT06697353
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
Bayer 4936 participants Est. completion 2025-09-19 1 siteHeart failureView official trial listing → -
Completed NCT NCT06708091
Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
Servier Affaires Médicales 537 participants Est. completion 2024-05-31 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT06731231
SGLT2i in Diabetic Patients with Renal Transplantation
Not yet reported, Not yet reported Ain Shams University 72 participants Est. completion 2025-01 1 siteOther conditions: Post-transplant Diabetes MellitusView official trial listing → -
Not yet recruiting NCT NCT06762223
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
Not yet reported Xiqiao Zhou 190 participants Est. completion 2026-12-31 1 site Stand-aloneMASLDType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT06794710
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
Not yet reported RenJi Hospital 300 participants Est. completion 2027-09-30 1 site Stand-aloneOther conditions: Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Metabolic Cardiomyopathy, Restrictive CardiomyopathyView official trial listing → -
Active, not recruiting NCT NCT06813222
Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin
Damanhour University 100 participants Est. completion 2025-03-01 1 siteChronic kidney disease Other conditions: AnemiaView official trial listing → -
Completed NCT NCT06825156
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 60 participants Est. completion 2023-05-26 1 siteOther conditions: Acute Kidney InjuryView official trial listing → -
Not yet recruiting NCT NCT06851845
Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
Novartis Pharmaceuticals 100 participants Est. completion 2028-02-01Other conditions: Kidney DiseasesView official trial listing → -
Active, not recruiting NCT NCT06901609
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Ain Shams University 200 participants Est. completion 2025-07-01 1 siteHeart failure Other conditions: Cardiac Fibrosis, Cardiac RemodelingView official trial listing → -
Completed NCT NCT06902493
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
University of Jazan 664 participants Est. completion 2025-03-01 1 siteOther conditions: Sepsis, Septic Shock, Acute Kidney InjuryView official trial listing → -
Active, not recruiting NCT NCT06933355
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
Not yet reported Odense University Hospital 8 participants Est. completion 2026-06-01 1 siteOther conditions: Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI), Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial, Placebo Control DesignView official trial listing → -
Not yet recruiting NCT NCT07032116
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
Liu Hongfang 4472 participants Est. completion 2028-07-31 5 sitesChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07044700
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Boehringer Ingelheim 5000 participants Est. completion 2028-12-31 1 siteHeart failureView official trial listing → -
Withdrawn NCT NCT07057479
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
Not yet reported Eurofarma Laboratorios S.A. Est. completion 2028-02 1 site Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07060417
Vascular Effects of SGLT2i in Non-diabetic CKD
Not yet reported VA Office of Research and Development 52 participants Est. completion 2029-09-30 1 siteChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07105917
SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 1050 participants Est. completion 2026-11-01 Stand-aloneCardiovascular diseaseView official trial listing → -
Not yet recruiting NCT NCT07108985
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
Not yet reported Yonsei University 100 participants Est. completion 2030-08-31 1 siteType 2 diabetes Other conditions: Hyperglycemia, Insulin ResistanceView official trial listing → -
Not yet recruiting NCT NCT07146880
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Not yet reported National Taiwan University Hospital 10 participants Est. completion 2027-09-21 1 siteOther conditions: Brugada Syndrome (BrS)View official trial listing → -
Active, not recruiting NCT NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University 23280000 participants Est. completion 2029-06-30 1 siteMetabolic syndromeView official trial listing → -
Not yet recruiting NCT NCT07211802
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Not yet reported University of California, San Diego 52 participants Est. completion 2030-12-31 1 site Added to GLP-1Other conditions: Type 1 Diabetes (T1D)View official trial listing → -
Active, not recruiting NCT NCT07241702
EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.
Attikon Hospital 100 participants Est. completion 2025-12-01 1 siteOther conditions: Type 1 DiabetesView official trial listing → -
Not yet recruiting NCT NCT07270198
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
Not yet reported Mario Negri Institute for Pharmacological Research 100 participants Est. completion 2027-08 1 siteChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07272057
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
Not yet reported Shanghai Chest Hospital 200 participants Est. completion 2026-11-07Other conditions: Lung CancerView official trial listing → -
Not yet recruiting NCT NCT07295522
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
Not yet reported IRCCS Policlinico S. Donato 368 participants Est. completion 2028-06-08 13 sites Stand-aloneHeart failureView official trial listing → -
Active, not recruiting NCT NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 siteType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07331220
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction
Not yet reported Nanjing First Hospital, Nanjing Medical University 310 participants Est. completion 2028-12-30 1 site Stand-aloneHeart failureView official trial listing → -
Not yet recruiting NCT NCT07348484
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Instituto de Investigación Biomédica de Salamanca 300 participants Est. completion 2028-03 1 siteChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07349979
PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF
Not yet reported Nanjing First Hospital, Nanjing Medical University 1154 participants Est. completion 2028-01-30 1 siteHeart failureCardiovascular disease Other conditions: Stable GDMTView official trial listing → -
Not yet recruiting NCT NCT07351643
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Not yet reported Shenyang Northern Hospital 110 participants Est. completion 2026-12-30 1 siteOther conditions: ACS (Acute Coronary Syndrome), SGLT2 InhibitorsView official trial listing → -
Not yet recruiting NCT NCT07424430
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
LMC Diabetes & Endocrinology Ltd. 400 participants Est. completion 2026-05Type 2 diabetes Other conditions: Diabetes (DM), Obesity (Disorder)View official trial listing → -
Not yet recruiting NCT NCT07436663
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Not yet reported Tanta University 150 participants Est. completion 2027-12-01Other conditions: Breast CancerView official trial listing → -
Completed NCT NCT07465926
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
Chung Shan Medical University 451036 participants Est. completion 2026-01-31Metabolic syndromeCardiovascular diseaseType 2 diabetes Other conditions: Kidney Disease, Obesity & OverweightView official trial listing → -
Active, not recruiting NCT NCT07471802
Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 150 participants Est. completion 2031-09-01 1 siteHeart failure Other conditions: Diabete Type 2, Kidney Disease, Chronic, Cardiorenal SyndromeView official trial listing → -
Not yet recruiting NCT NCT07488689
Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction
Not yet reported University Hospital, Strasbourg, France 568 participants Est. completion 2030-07 1 siteOther conditions: Septic ShockView official trial listing → -
Not yet recruiting NCT NCT07537088
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Not yet reported First Affiliated Hospital of Wannan Medical College 468 participants Est. completion 2027-07 Added to GLP-1Type 2 diabetesChronic kidney diseaseView official trial listing → -
Completed NCT NCT07566299
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
Chung Shan Medical University 118805 participants Est. completion 2026-03-31Type 2 diabetesMetabolic syndromeMASLDView official trial listing → -
Not yet recruiting NCT NCT07580638
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
Chipscreen Biosciences, Ltd. 3550 participants Est. completion 2028-07-18Type 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT07586371
Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i
Not yet reported, Not yet reported Dr Mudassar Saeed Pansota 60 participants Est. completion 2026-08-05 1 site Stand-aloneOther conditions: Proteinuria, Diabetes (DM)View official trial listing → -
Completed NCT NCT07627048
Influence of Gut Microbiota on the Development of Type 2 Diabetes Mellitus and Personalization of Diabetes-lowing Therapy
Pirogov Russian National Research Medical University 100 participants Est. completion 2022-04-10 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT07628556
Antidiabetic Medications and Risk of Cancer
University of Pecs 74799 participants Est. completion 2025-12-30 1 siteOther conditions: CancerView official trial listing → -
Not yet recruiting NCT NCT07668739
Efficacy of Verciguat in TR and RV Failure
Not yet reported Daejeon St. Mary's hospital 100 participants Est. completion 2028-05-31 1 site Stand-aloneOther conditions: HFrEF, Tricuspid Regurgitation (TR)View official trial listing → -
Not yet recruiting NCT NCT07682350
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
Not yet reported Odense University Hospital 184 participants Est. completion 2029-10-01 3 sitesOther conditions: Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial (RCT), Placebo Control Design, Post Transplant Diabetes MellitusView official trial listing → -
Not yet recruiting NCT NCT07687212
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
Not yet reported, Not yet reported The First Affiliated Hospital of Air Force Medicial University 162 participants Est. completion 2027-11 1 siteHeart failureView official trial listing → -
Completed NCT NCT07708025
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients
Not yet reported Universidade do Porto 55 participants Est. completion 2026-03-15 1 siteHeart failure Other conditions: AnemiaView official trial listing → -
Not yet recruiting NCT NCT07708610
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
Chung Shan Medical University 71775 participants Est. completion 2026-08-31 1 site Stand-aloneType 2 diabetes Other conditions: PneumoniaView official trial listing → -
Not yet recruiting NCT NCT07714239
Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure
Not yet reported VA Office of Research and Development 585 participants Est. completion 2030-09-30 1 site Stand-aloneHeart failureView official trial listing → -
Not yet recruiting NCT NCT07723820
Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE)
Thammasat University Hospital 126 participants Est. completion 2027-09-01 1 siteType 2 diabetes Other conditions: Diabetic Retinopathy (DR)View official trial listing → -
Not yet recruiting NCT NCT07766109
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
Not yet reported University Hospital, Toulouse 434 participants Est. completion 2029-01 1 siteHeart failure Other conditions: Cardiac SurgeryView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.